nimotuzumab + penpulimab + docetaxel + cisplatin

This combination therapy is a multi-agent chemo-immunotherapy regimen being investigated as an induction treatment for locally advanced head and neck squamous cell carcinoma (HNSCC). It consists of two monoclonal antibodies—**nimotuzumab**, which targets the epidermal growth factor receptor (EGFR), and **penpulimab**, a checkpoint inhibitor targeting programmed cell death protein 1 (PD-1)—alongside the standard **TP** chemotherapy doublet of **docetaxel** and **cisplatin**. Nimotuzumab works by binding to EGFR, thereby inhibiting tumor cell proliferation and angiogenesis, while penpulimab restores the anti-tumor activity of T-cells by blocking the PD-1/PD-L1 pathway. The chemotherapy components, docetaxel and cisplatin, provide cytotoxic effects by stabilizing microtubules and inducing DNA cross-linking, respectively. This quadruple combination is primarily being developed and studied by researchers at Xijing Hospital to improve response rates and survival in patients with advanced HNSCC.

Brand names

Taixin

Other names

TP + nimotuzumab + penpulimabNimotuzumab and Penpulimab Combined With Docetaxel and Cisplatin